Benitec Biopharma Inc. (BNTC) has a consensus analyst rating of Buy, based on 7 analysts covering the stock. Of those, 6 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for BNTC is $27.00, representing a +103.8% upside from the current price of $13.25. Price targets range from a low of $22.00 to a high of $32.00.
